HCC CONNECT has summarised the highlights from ESMO 2018 for you
Hepatocellular carcinoma by Dr. Changhoon Yoo, Asan Medical Center, University of Ulsan College of Medicine, Korea
Dr Changhoon Yoo is a medical oncologist who specialises in the care of patients with gastrointestinal cancers including hepatocellular carcinoma. He is an Assistant Professor at Asan Medical Center in Seoul, South Korea. Dr Yoo obtained his medical degree at the University of Ulsan College of Medicine, Seoul, South Korea and completed post graduate training at Asan Medical Center. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with hepatocellular carcinoma. His research initiatives include the integration of novel targeted and immune-based therapy into the treatment of hepatocellular carcinoma. Relevant publications Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, Yoo C, Yi K, Kim KH, Eo S, Moon DB, Hong SM, Ju YS, Shin EC, Hwang S, Park SH. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology 2018 Aug 23; pii: S0016-5085(18)34897-2. doi: 10.1053/j.gastro.2018.08.030. [Epub ahead of print] PMID: 30145359 Yoo C, Kang J, Lim HY, Kim JH, Lee MA, Lee KH, Kim TY, Ryoo BY. Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat 2018 Jun 13. doi: 10.4143/crt.2018.226. [Epub ahead of print] PMID: 29898591 Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. Int J Biol Markers 2018 Jun 1:1724600818777239. doi: 10.1177/1724600818777239. [Epub ahead of print] PMID: 29874985 Cho H, Yoo C, Kim KP, Jeong JH, Kang J, Chang HM, Lee SS, Park DH, Song TJ, Lee SK, Kim MH, Lee HC, Lim YS, Kim KM, Shim JH, Hwang S, Song GW, Moon DB, Lee JH, Lee YJ, Ryoo BY. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. Invest New Drugs 2018 Jun;36(3):496-502. doi: 10.1007/s10637-017-0548-7. Epub 2017 Dec 1. PMID: 29192354 Yoo C, Kang J, Kim D, Kim KP, Ryoo BY, Hong SM, Hwang JJ, Jeong SY, Hwang S, Kim KH, Lee YJ, Hoeflich KP, Schmidt-Kittler O, Miller S, Choi EK. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.
Asst. Prof. Changhoon Yoo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Bayer, Eisai, MSD, Ono and Ipsen.
Experts
Dr Su Pin Choo-
Downloadable
Resouces -
5 MIN
-
Sep 2021
Downloadable 
5 MIN
Sep 2021 
Experts
Dr Su Pin Choo-
Downloadable
Resouces -
5 MIN
-
Sep 2021
Download the slides 
Programme summary
Duration 5 MIN- Downloadable resources Yes
-
Download the slides
- Language(s)
Duration 
Language(s) 
Share this programme
Brought to you by
HCC CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.
Meet the expertsOther programmes of interest
Video
Oncology
Celebrating the 10th anniversary of GI CONNECT
10 years of independent medical education in GI oncology
Experts
Assoc. Prof. Gerald Prager, Assoc. Prof. Joleen Hubbard, Dr Thomas Winder, Prof. Andrea Sartore-Bianchi, Dr Dominik Modest-
2 MIN
-
Apr 2024
Tweetorial
Oncology
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond
Journey through a patient case from testing and diagnosis to treatment and AE management
Experts
Dr Aditya BardiaEndorsed by
-
11 MIN
-
Apr 2024
Podcast
Oncology
Perseverance in molecular testing in NSCLC pays off
Looking beyond the obvious mutations in non-small-cell lung cancer
Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski-
Downloadable
Resources -
26 MIN
-
Mar 2024
Conference update
Oncology
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo-
Downloadable
Resources -
6 MIN
-
Mar 2024
Podcast
Oncology
mCRC: Optimising patient outcomes with late-line treatment
Maximising outcomes for patients with advanced CRC
Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de JesusEndorsed by
-
Downloadable
Resources -
23 MIN
-
Mar 2024
Interactive patient case
Oncology
TRK fusion-positive lung cancer: Diagnosis and treatment
Make decisions for your patient at two key stages in their journey
Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski-
60 MIN
-
Mar 2024
